Author(s): Goldman SA
Abstract Share this page
Abstract US Food and Drug Administration (FDA) monitoring of the continued safety of marketed medical products depends greatly on spontaneous reporting of serious adverse events by health professionals. Despite its inherent limitations, the national postmarketing surveillance system provides vital information of clinical importance.
This article was published in Clin Ther
and referenced in Journal of Pharmacovigilance